Search clinical trials for: CPG-oligonucleotide

Total 2392 results

Assistance Publique - Hôpitaux de Paris

Completed

Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma

Glioblastoma

France
SBI Biotech Co., Ltd.

Terminated

A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Leukemia

United States
University of Aarhus

Completed

Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection (TEACH)

HIV

Denmark
Second Affiliated Hospital of Guangzhou Medical...
Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

Recruiting

Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors

Hepatocellular Carcinoma | Lung Cancer | Solid Tumor

China
Brigham and Women's Hospital

Unknown

24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients

Amyloidosis

United States
University of Saskatchewan

Not yet recruiting

Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer

Liver Metastasis Colon Cancer
Valneva Austria GmbH

Recruiting

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

Zika | Zika Virus Infection

United States
Dynavax Technologies Corporation
United States Department of Defense

Completed

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Vaccine-Preventable Diseases | Plague | Plague, Pneumonic

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin... and other conditions

United States
Brigham and Women's Hospital
GlaxoSmithKline; Ionis Pharmaceuticals, Inc.

Withdrawn

The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart

Amyloidosis
Baylor College of Medicine
George Washington University

Completed

Safety and Immunogenicity Study of Na-GST-1 With or Without CpG

Hookworm Infection | Hookworm Disease

United States
Massachusetts General Hospital
n-Lorem Foundation

Not yet recruiting

Single Participant Study of an Experimental ASO Treatment for TUBB4A-related Leukodystrophy

Genetic Disease
Bio-Path Holdings, Inc.

Recruiting

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Follicular Lymphoma | Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | DLBCL | Cutaneous T-cell Lymphoma (CTCL) | Peripheral T-cell Lymphoma (PTCL)

United States
Clover Biopharmaceuticals AUS Pty Ltd

Terminated

Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases (COVID-19)

COVID-19

Ukraine
ProQR Therapeutics

Active, not recruiting

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, Netherlands, United Kingdom, Germany
Dynavax Technologies Corporation

Terminated

A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer

Colorectal Neoplasms

United States
Ministry of Public Health of the Province of La...
Immunalgia Therapeutics S.A.

Recruiting

Safety and Pharmacokinetics of IMT504, an Immunomodulator and Tissue Repair Inducer (ECDA000/02)

Immune System

Argentina
Isarna Therapeutics GmbH

Completed

Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy

Primary Open Angle Glaucoma

Germany
Bionos Biotech S.L.

Completed

Bioavailability of Different Collagen-based Treatments After Oral Intake

Healthy Volunteers

Spain
Novartis Pharmaceuticals

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

Progressive Supranuclear Palsy (PSP)

Germany, United Kingdom, Canada, United States
ProQR Therapeutics

Terminated

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, United Kingdom
ProQR Therapeutics

Terminated

An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (HELIA)

Retinitis Pigmentosa | Usher Syndrome Type 2

United States, Canada, France
Clover Biopharmaceuticals AUS Pty Ltd
International Vaccine Institute; Coalition for Epidemic Preparedness Innovations

Completed

A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)

COVID-19

Colombia, Belgium, Brazil, Philippines, South Africa
Ronald Levy
American Society of Clinical Oncology; Lymphoma Research Foundation

Completed

CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas

Mycosis Fungoides | Non-Hodgkin Lymphoma

United States
University Hospital, Grenoble
Clinical Investigation Centre for Innovative Technology Network; University... and other collaborators

Completed

Computer-assisted Fetal Monitoring - Obstetrics (SURFAO-Obst)

ECG-PCG-CTG Acquisition on Pregnant Voluntary Subjects

France
Dynavax Technologies Corporation

Completed

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

Hepatitis B

United States
University of Washington
Seattle Children's Hospital; University of Nairobi

Completed

Oligonucleotide Ligation Assay (OLA) Resistance Study (OLA)

HIV Positive

Kenya
Ahram Canadian University

Completed

Post-instrumentation Pain After Use of the Fanta and M3 Pro Gold Systems

Endodontic Treatment

Egypt
Genta Incorporated

Completed

A Phase I Study of G3139 Subcutaneous in Solid Tumors

Tumors

United States
University of Maryland, Baltimore

Recruiting

Testing the Pain Clinical Practice Guideline

Pain | Dementia

United States
Ronald Levy
Pfizer

Completed

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

Lymphoma | Lymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell

United States
ProQR Therapeutics

Completed

Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Stellar)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, Canada, France
Bio-Path Holdings, Inc.

Recruiting

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

Fallopian Tube Neoplasms | Carcinoma, Ovarian Epithelial | Solid Tumor | Endometrial Cancer | Peritoneal Cancer | Solid Tumor, Adult

United States
University of Iowa
National Cancer Institute (NCI); Mayo Clinic; Pfizer

Completed

A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated

Chronic Lymphocytic Leukemia

United States
Stanford University
National Institutes of Health (NIH)

Withdrawn

Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.

Mycosis Fungoides
NYU Langone Health
Alzheimer's Association

Recruiting

Innate Immunity Stimulation Via TLR9 in Early AD

Mild Cognitive Impairment | Alzheimer Dementia

United States
Brooke Army Medical Center
University of Utah

Recruiting

Non-Surgical Management of Knee Osteoarthritis in the Military Health System (MHS)

Knee Osteoarthritis

United States
Incheon St.Mary's Hospital

Withdrawn

Optimal Tailored Treatment for H. Pylori Infection

Helicobacter Pylori Infection | Antibiotic Resistant Infection

Korea, Republic of
National Institute of Allergy and Infectious Diseases...
Fred Hutchinson Cancer Center; International AIDS Vaccine Initiative; HIV Vaccine... and other collaborators

Active, not recruiting

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

HIV Infections

United States
Clover Biopharmaceuticals AUS Pty Ltd

Completed

SCB-2019 as COVID-19 Vaccine

COVID-19

Australia
Chinese University of Hong Kong
Integrated Community Centers for Mental Wellness

Active, not recruiting

Effects of an Acceptance-based Medication Adherence Therapy for Recent-onset Psychosis (AIM_AT)

Psychotic Disorders | Early Psychosis

Hong Kong
Pfizer

Completed

CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer

Carcinoma, Breast

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Withdrawn

Biomarkers in Tissue Samples From Patients Who Have Undergone Neck Dissection for Oral Cancer

Head and Neck Cancer

United States
Pfizer

Completed

CPG 7909 in Patients Wih Stage IV Renal Cell Cancer

Carcinoma, Renal Cell
Genta Incorporated

Completed

Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

Solid Tumors

United States
Pfizer

Completed

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Melanoma | Carcinoma, Renal Cell | Breast Neoplasms | Carcinoma, Non-Small-Cell Lung | Lymphoma, T-Cell

United States, Germany
Pfizer

Completed

CPG 7909 in Patients With Cutaneous T-Cell Lymphoma

Lymphoma, T-Cell, Cutaneous
University of Jena

Completed

Nutritional Evaluation of Canola Protein in Comparison With Soy Protein

Men

Germany
Seoul National University Hospital

Unknown

Empirical vs Tailored Therapy for H. Pylori Infection

Helicobacter Pylori Infection | Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation

Korea, Republic of
Ronald Levy
National Institutes of Health (NIH)

Completed

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

Lymphoma, Mantle-Cell

United States

Search clinical trials for: CPG-oligonucleotide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations